Eli Lilly and Company (NYSE:LLY) Shares Sold by Congress Park Capital LLC

Congress Park Capital LLC reduced its stake in Eli Lilly and Company (NYSE:LLY) by 5.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,252 shares of the company’s stock after selling 181 shares during the period. Eli Lilly and Company accounts for about 1.1% of Congress Park Capital LLC’s investment portfolio, making the stock its 29th biggest holding. Congress Park Capital LLC’s holdings in Eli Lilly and Company were worth $2,530,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Truvestments Capital LLC boosted its stake in Eli Lilly and Company by 13.9% in the third quarter. Truvestments Capital LLC now owns 410 shares of the company’s stock valued at $220,000 after acquiring an additional 50 shares during the period. Trexquant Investment LP acquired a new position in shares of Eli Lilly and Company during the third quarter worth approximately $3,874,000. Trustmark National Bank Trust Department boosted its position in shares of Eli Lilly and Company by 123.3% during the third quarter. Trustmark National Bank Trust Department now owns 2,302 shares of the company’s stock worth $1,236,000 after buying an additional 1,271 shares during the period. Roundview Capital LLC boosted its position in shares of Eli Lilly and Company by 1.8% during the third quarter. Roundview Capital LLC now owns 2,328 shares of the company’s stock worth $1,250,000 after buying an additional 41 shares during the period. Finally, Private Advisory Group LLC boosted its position in shares of Eli Lilly and Company by 6.3% during the third quarter. Private Advisory Group LLC now owns 16,788 shares of the company’s stock worth $9,018,000 after buying an additional 988 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.4 %

NYSE:LLY traded up $3.29 during trading hours on Friday, reaching $912.33. The company’s stock had a trading volume of 987,494 shares, compared to its average volume of 2,917,893. The company has a market cap of $867.09 billion, a price-to-earnings ratio of 134.57, a price-to-earnings-growth ratio of 1.97 and a beta of 0.36. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a one year low of $434.34 and a one year high of $915.54. The business’s 50-day moving average is $807.55 and its 200-day moving average is $735.35.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.62 earnings per share. Equities research analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LLY. Truist Financial reiterated a “buy” rating and set a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday. Jefferies Financial Group boosted their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday. BMO Capital Markets boosted their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $812.72.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 17,229 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $902.38, for a total value of $15,547,105.02. Following the completion of the transaction, the insider now owns 97,556,910 shares of the company’s stock, valued at $88,033,404,445.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 17,229 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $902.38, for a total transaction of $15,547,105.02. Following the completion of the sale, the insider now owns 97,556,910 shares of the company’s stock, valued at $88,033,404,445.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders sold 789,704 shares of company stock valued at $672,385,964 over the last quarter. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.